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Pharmacology of prostaglandin analogues
These drugs are lipid structural derivatives 
and are synthetic prostaglandin F2a 
analogues.3 They are actually prodrugs 
and these arachidonic acid derivatives 
are hydrolyzed by corneal esterases to a 
biologically active free acid. Bimatoprost is a 
subclass and is actually a prostamide rather 
than a prostaglandin analogue. Prostamides 
do not appear to bind to prostaglandin FP 
receptor as PG analogues. 
Mechanism of Action 
Prostaglandin analogues increase uveoscleral 
outflow rather than altering conventional 
trabeculo-canalicular aqueous outflow.4 
The IOP-lowering effect of latanoprost 
lasts for 20 to 24 hours after a single dose, 
which allows a single daily dosage regimen. 
Data from four randomized double-masked 
multicentre studies indicate that a once daily 
dose of topical latanoprost 0.005% is as 
effective as timolol 0.5% twice daily in the 
treatment of patients with primary open-
angle glaucoma or ocular hypertension.5





matrix surrounding the ciliary muscle 
cells (modulation of tissue matrix 
metalloproteinases) 
•	 Altered	cellular	morphology.6
Uveoscleral outflow does not end in the 
episcleral venous circulation so it is possible 
to get an intraocular pressure around 
episcleral venous pressure (~10mmHg).7 
This is very important especially in normal 
tension glaucoma where optic nerve damage 
occurs in the presence of lower intraocular 
pressures. 
Bimatoprost is an active drug in contrast 
to latanoprost and travoprost which, as 
described above, require activation by 
corneal enzymes. Bimatoprost increase 
aqueous outflow by increasing both 
trabecular outflow facility and uveoscleral 
outflow. 
Latanoprost 0.005% once daily was 
compared to timolol 0.5% twice daily in 
three large studies. The former reduced 
the IOP by around 30% and was found to 
be predominantly more effective than the 
beta-blocker. Peak effect of PG analogues 
occurs 12 hours post-instillation. There was 
no loss of effect after a year. Travoprost 
is very similar to latanoprost, though the 
The history of glaucoma pharmacology begins in 1862 with the 
isolation of physostigmine from the calabar bean.1 The discovery of 
epinephrine’s intraocular pressure lowering capacity came just after 
WWI. During the 20th century, drug discovery and development 
accelerated, with the introduction of carbonic anhydrase inhibitors, 
beta-blockers (1970s), alpha-agonists and lately prostanoids(1990s).2 
Prostanoids have been divided into PG analogues and prostamides 
because of differences in molecular structures. The drugs share a novel 
mechanism of action that produces a potent ocular hypotensive effect 
and a novel local adverse effect of increased iridial pigmentation. 
Anti-glaucoma medication targets different key pathophysiological 
aspects of the disease and overlap in the mechanisms of action of 
these drugs proved to be important. The development of a completely 
new class of drugs added to the suppressive armamentarium against 
this blinding condition. More drug variety skewed glaucoma care away 
from the theatre, effectively changing the timing of glaucoma surgery. 
Issue 17  Summer 2011 Journal of the Malta College of Pharmacy Practice          35
Table 1. Commercially available prostanoids in drop form







former binds to the FP receptor with a higher 
affinity. They have the same mechanism 
of action and are prescribed once daily, 
preferably in the evening.8
Bimatoprost was also compared to 
timolol and was found to be much more 
superior in efficacy. An interesting trial 
comparing the three drugs for 12 weeks 
found no statistical significance in the 
difference of IOP lowering, however in the 
long term (6months), bimatoprost was 
found to be more effective. Some glaucoma 
specialists postulate a switch from one 
prostanoid to another. This was hinted 
at in a study that showed that patients 
who were not responsive to latanoprost 
have a likelihood of 13/15 of obtaining at 
least 20% reduction in IOP if switched to 
bimatoprost.9 In certain situations one might 
also combine a prostaglandin analogue with 
the prostamide bimatoprost, especially in 
the presence of multiple intolerance to other 
anti-glaucoma medications.
There is evidence that latanoprost 
lowers IOP in angle-closure glaucoma and its 
efficacy is not related to angle width.10
Role of Combination therapy
Combining an aqueous suppressant with 
a prostaglandin analogue enhances IOP-
lowering effect as both aqueous inflow and 
outflow are targeted. For example, combining 
latanoprost 0.005% once daily with timolol 
0.5% twice daily achieves 13-30% increase 
in IOP-lowering effect.11
Prostaglandin analogues side effects
Table 2 shows an exhaustive list of known 
side-effects of prostaglandin analogues. 
More specific side-effects
Iris pigmentation12 - Eyes with a concentric 
heterochromia (more pigment around the 
pupil than in the periphery) before treatment 
are more at risk of iris pigmentation. Eyes 
that already have more iris melanocytes 
are more prone to pigmentation. Hence 
green-brown eyes are more at risk than 
blue or blue-grey irises. PG analogues do 
not cause iris melanocyte proliferation but 
merely stimulate these cells to produce more 
melanin hence making this iris look darker.13 
Iris pigmentation is irreversible and seems 
to be least associated with bimatoprost. Iris 
naevi are not affected by PG analogues. 
Hyperaemia14 This is conjunctival 
injection which is not related to an allergic 
follicular conjunctival response or actual 
tissue inflammation. The bimatoprost–related 
hyperameia was mild to moderate and only 
4% of patients using this drug stopped 
treatment because of this. This hyperaemia 
is sometimes compounded with a burning 
sensation and occurs primarily at the initial 
stages of treatment and eventually improves. 
Clinical examination did not show an 
increased anterior chamber flare. 
Meibomian gland disease is slightly more 
prevalent with prostaglandin analogues 
because they may stimulate meibomian 
gland secretion which may predispose to 
the formation of chalazia and seborrhoeic 
blepharitis.15 
Eyelash growth - Some consider this 
as a beneficial side-effect. Some recent 
topical preparations exist which contain 
a prostaglandin analogue to minimize 
radiation-induced eyelash loss in an 
oncological setup.16 
Prostaglandin analogues increase the risk 
of macular oedema because there is evidence 
that they alter blood-ocular barrier especially 
in pseudophakic and aphakic patients.17
Periorbital fat atrophy.18 This visually 
noticeable side effect has features 
demonstrable on MRI scanning. The 
periorbital fat atrophy is most apparent with 
uniocular use and both doctors and patients 
need to be aware of this side effect before 
commencing treatment. The effects, however, 
appear to be reversible with treatment 
cessation.
Systemic safety of prostaglandin analogues
Latanoprost has a plasma half-life of 17 
minutes and is administered in very low doses 
so only minimal side effects are anticipated. 
No effect was found on cardiovascular 
integrity, metabolic function and the 
haematologic profile of the human body. 
Tafluprost
Tafluprost is a recent addition to the 
prostaglandin analogue spectrum of drugs 
and is already commercially available. Early 
studies comparing tafluprost with the earlier 
travoprost 0.004% found that travoprost 
0.004% monotherapy produced lower diurnal 
IOP than tafluprost 0.0015% in patients 
with primary open-angle glaucoma or ocular 
hypertension, but exhibited a similar safety 
profile.19
Table 2. Prostaglandin analogues side effects
Side Effect Incidence/comment
Non-specific
Conjunctival hyperaemia 36%, more prominent with bimatoprost
Burning and stinging 25%
Blurred vision 17%
Pruritus 15%
Foreign body sensation 33%
Tearing 6%
Ocular pain 13%
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When to use what type of Prostanoid
It is important to be aware that not all 
these types of prostanoids were available 
to prescribe all at once and historically 
molecular modifications were implied so 
as to make the newer drug more efficient 
with less potential side-effects. As pointed 
above, all the prostanoids have similar 
therapeutic effects but overall they changed 
the approach of treating glaucoma, as it was 
found out that they are very effective as 
first-line drugs.20 
Conclusion
The introduction of a new class of IOP-
lowering drug with a completely different 
mode of action to the already existing ones 
slows down the pathophysiological process 
of this optic neuropathy. High intraocular 
pressure is one of the most prominent risk 
factors for the development of glaucoma. 
Anomalous ocular blood flow orchestrated by 
endothelin also contributes to this disease 
progression. Current studies are on the go to 
identify new molecular structures that have 
anti-endothelin effects in the context of 
disease progression in glaucoma in patients 
with a normal intraocular pressure. 
References
5 Zhang WY, Po AL, Dua HS, Azuara-Blanco A. 
Meta-analysis of randomised controlled trials 
comparing latanoprost with timolol in the 
treatment of patients with open angle glaucoma 
or ocular hypertension. Br J Ophthalmol. 2001 
Aug;85(8):983-90.
6 Toris CB, Gabelt BT, Kaufman PL. Update on the 
mechanism of action of topical prostaglandins for 
intraocular pressure reduction. Surv Ophthalmol. 
2008 Nov;53 Suppl1:S107-20.
7 Kaufman PL, Crawford K. Aqueous humor 
dynamics: how PGF2 alpha lowers intraocular 
pressure. Prog Clin Biol Res. 1989;312:387-416.
8 Netland PA, Landry T, Silver LH, et al. IOP-
lowering efficacy and safety of travoprost 
compared to latanoprost and timolol in patients 
with open-angle glaucoma or ocular hypertension. 
Invest. Ophthalmol Vis. Sci. Suppl. 2001;42:S556
9 Gandolfi SA, Cimino L, Mora P. Effect of 
brimonidine on intraocular pressure in normal 
tension glaucoma: a short term clinical trial. Eur J 
Ophthalmol. 2003 Aug-Sep;13(7):611-5.
10 Aung T, Chan YH, Chew PT; EXACT Study Group. 
Degree of angle closure and the intraocular 
pressure-lowering effect of latanoprost in 
subjects with chronic angle-closure glaucoma. 
Ophthalmology. 2005 Feb;112(2):267-71.
11 Olander K, Zimmerman TJ, Downes N, 
Schoenfelder J; Xalacom/Latanoprost Study 
Group. Switching from latanoprost to fixed-
combination latanoprost-timolol: a 21-day, 
randomized, double-masked, active-control 
study in patients with glaucoma and ocular 
hypertension. Clin Ther. 2004 Oct;26(10):1619-29.
12 Alm A, Stjernschantz J. Effects on intraocular 
pressure and side effects of 0.005% latanoprost 
applied once daily, evening or morning. 
A comparison with timolol. Scandinavian 
Latanoprost Study Group. Ophthalmology. 1995 
Dec;102(12):1743-52.
13 Selén G, Stjernschantz J, Resul B. Prostaglandin-
induced iridial pigmentation in primates.Surv 
Ophthalmol. 1997 Feb;41 Suppl 2:S125-8. 
14 Craven ER, Liu CC, Batoosingh A, Schiffman RM, 
Whitcup SM. A randomized, controlled comparison 
of macroscopic conjunctival hyperemia in patients 
treated with bimatoprost 0.01% or vehicle who 
were previously controlled on latanoprost. Clin 
Ophthalmol. 2010 Dec 6;4:1433-40.
15 Cunniffe MG, Medel-Jiménez R, González-
Candial M. Topical Antiglaucoma Treatment 
With Prostaglandin Analogues May Precipitate 
Meibomian Gland Disease. Ophthal Plast Reconstr 
Surg. 2010 Dec 20. 
16 Bikowski J, Lau EG, Jacob SE. Eyelash growth: a 
beneficial side effect of prostaglandin analogues. 
Cutis. 2010 Apr;85(4):187-8.
17 Arcieri ES, Santana A, Rocha FN, Guapo GL, Costa 
VP. Blood-aqueous barrier changes after the 
use of prostaglandin analogues in patients with 
pseudophakia and aphakia: a 6-month randomized 
trial. Arch Ophthalmol. 2005 Feb;123(2):186-92.
18 Jayaprakasam A, Ghazi-Nouri S. Periorbital 
fat atrophy - an unfamiliar side effect 
of prostaglandin analogues. Orbit. 2010 
Dec;29(6):357-9.
19 Schnober D, Hofmann G, Maier H, Scherzer ML, 
Ogundele AB, Jasek MC. Diurnal IOP-lowering 
efficacy and safety of travoprost 0.004% compared 
with tafluprost 0.0015% in patients with primary 
open-angle glaucoma or ocular hypertension. Clin 
Ophthalmol. 2010 Dec 8;4:1459-63.
20 Denis P, Baudouin C, Bron A, Nordmann JP, 
Renard JP, Rouland JF, Sellem E, Amrane M. First-
line latanoprost therapy in ocular hypertension or 
open-angle glaucoma patients: a 3-month efficacy 
analysis stratified by initial intraocular pressure. 
BMC Ophthalmol. 2010 Feb 24;10:4.
Key points
•	 The	drugs	share	a	novel	mechanism	of	action	that	produces	a	potent	ocular	
hypotensive effect.
•	 Prostaglandin	analogues	increase	uveoscleral	outflow	rather	than	altering	conventional	
trabeculo-canalicular aqueous outflow.
